RailTel Corporation of India Limited has received a Letter of Acceptance from Assam Health Infrastructure Development & Management Society for an HMIS project valued at ₹56.71 crore, as per NSE disclosure dated 1 January 2026. The contract covers procurement, implementation, and maintenance.
Source: RailTel Corporation of India Limited Press Release (NSE Exchange Filings) | Published on Jan 01, 2026
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from RailTel Corporation of India Limited (NSE Exchange Filings), Assam Health Infrastructure Development and Management Society (AHIDMS) has awarded the Company a Letter of Acceptance related to the procurement, implementation, and provision of maintenance for the Hospital Management Information System (HMIS).
According to the disclosure made to the stock exchange, it is estimated that the size of the order will amount to Rs 56.71 crore. This information has been submitted to the National Stock Exchange in accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The Company received this order from an entity based in India and is therefore required to report these disclosures as part of its normal business activity.
The filing records the order as a confirmed contract and does not include any forward-looking statements or assumptions.
Also Read: Vodafone Idea Receives ₹637.9 Crore GST Penalty Order
Value of the order: ₹56.71 crore
Assam Health Infrastructure Development & Management Society is in charge of giving out orders.
The type of order is a letter of acceptance.
Scope: Buying, setting up, and maintaining an HMIS
Time frame for execution: until January 31, 2032
An annex (in the Exchange Filings) indicates the project will also include procurement, implementation, and ongoing support/maintenance of a Hospital Management Information System (HMIS). The system is intended to support hospital operations under the Assam Health Infrastructure Framework.
The contract has been classified as a domestic order. The filing confirms that neither the promoter nor promoter group entities have any interest in the awarding authority. It also states that the contract does not fall under related party transactions.
The Project Execution Term is until 31 January 2032. AHIDMS has issued a Letter of Acceptance indicating that the size of the order is only an estimate. The complete information complies with the SEBI requirement for disclosure.
Particulars | Details |
Awarding Authority | Assam Health Infrastructure Development & Management Society |
Nature of Contract | Letter of Acceptance (LoA) |
Scope of Work | Procurement, implementation and maintenance of HMIS |
Order Value | ₹56.71 crore |
Contract End Date | 31 January 2032 |
Related Party Transaction | No |
From January 1, 2026, the ISSUING COMPANY sent the first notice to the STOCK EXCHANGE. The notice cites the SEBI CIRCULAR dated July 12, 2023, as providing enhanced disclosure requirements on material events in the form of an LOA.
The notification from the stock exchange acknowledges that they received the LOA on January 1, 2026, at 12:50 pm. The notification from the stock exchange also indicates there were no delays in reporting this event. This notification has been issued by the designated authority of the issuer.
All information shared in the filing is factual and limited to the confirmed terms of the order. No projections regarding revenue recognition or financial impact have been included.
As per the market data available on 1 January 2026 at 15:30 PM IST, the RailTel Corporation of India share price on the NSE stood at ₹370.95. The stock opened at ₹373.00 during the session and touched an intraday high of ₹374.25. The intraday low was recorded at ₹366.50. The previous closing price stood at ₹371.55.
Also Read: Aurobindo Pharma Subsidiary Buys Khandelwal Non-Oncology Business for ₹325 Crore
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading